Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Flumatinib mesylate (HHGV678 mesylate) 是一种具有口服活性的选择性Bcr-Abl 抑制剂,能够作用于 c-Abl (IC50:1.2 nM),PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 598 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,620 | 现货 | ||
25 mg | ¥ 3,230 | 现货 | ||
50 mg | ¥ 5,180 | 现货 | ||
100 mg | ¥ 7,660 | 现货 | ||
500 mg | ¥ 15,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 168 | 现货 |
产品描述 | Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants. |
体外活性 | In vivo study consistently suggested that flumatinib had superior efficacy compared with imatinib or sunitinib against 32D cells with the secondary mutation Y823D.?Molecular modeling of flumatinib docked to the KIT kinase domain suggested a special mechanism underlying the capability of flumatinib to overcome the drug-resistance conferred by activation loop mutations.?These findings suggest that flumatinib could be a promising therapeutic agent against GISTs resistant to both imatinib and sunitinib because of secondary mutations in the activation loop[1]. |
别名 | 甲磺酸氟马替尼/氟马替尼, HHGV678 mesylate, 甲磺酸氟马替尼 |
分子量 | 658.69 |
分子式 | C30H33F3N8O4S |
CAS No. | 895519-91-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (75.91 mM)
DMSO: 50 mg/mL (75.91 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 1.5182 mL | 7.5908 mL | 15.1816 mL | 37.9541 mL |
5 mM | 0.3036 mL | 1.5182 mL | 3.0363 mL | 7.5908 mL | |
10 mM | 0.1518 mL | 0.7591 mL | 1.5182 mL | 3.7954 mL | |
20 mM | 0.0759 mL | 0.3795 mL | 0.7591 mL | 1.8977 mL | |
50 mM | 0.0304 mL | 0.1518 mL | 0.3036 mL | 0.7591 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Flumatinib mesylate 895519-91-2 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl PDGFR c-Kit HHGV-678 PDGFRβ HHGV678 c-Abl Platelet-derived growth factor receptor Flumatinib Mesylate 甲磺酸氟马替尼/氟马替尼 HHGV 678 HHGV-678 Mesylate SCFR Flumatinib CD117 HHGV 678 Mesylate HHGV678 mesylate Inhibitor HHGV678 Mesylate inhibit 甲磺酸氟马替尼 inhibitor